

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known				
(Use several sheets if necessary)				Application Number	10/645,895			
				Filing Date	August 21, 2003			
				First Name Inventor	Hoffmann, et al.			
				Group Art Unit	1626-1625			
				Examiner Name	Shameem Golam M- ZNDAVIS			
Sheet 1 of 1				Attorney Docket Number	20693 US3			
U.S. PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY			
		Number	Kind Code <sup>3</sup> (if known)					
Mnd	A1	5,691,336		Dorn et al.	11/25/1997			
Mnd	A2	5,972,938		Rupniak et al.	10/26/1999			
Mnd	A3	6,297,375		Bos et al.	10/02/2001			
FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>4</sup>	
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
Mnd	B1	WO 95/16679			Merck & Co.	06/22/1995		
	B2	WO 95/18124			Merck, Sharpe & Dohme	07/06/1995		
	B3	WO 95/23798			Merck & Co.	09/08/1995		
	B4	EP 103 545			F.Hoffmann-La Roche	05/30/2001		
Mnd	B5	EP 035 115			F.Hoffmann-La Roche	09/13/2000		
NON PATENT LITERATURE DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T <sup>2</sup>	
Mnd	C1	Hans Bundgaard, <i>Drugs of the Future</i> , Vol. 16(5), pp. 443-458 (1991)						
	C2	Barker, <i>Reviews in the Neurosciences</i> , Vol. 7, No. 3, pp. 187-214 (1996)						
	C3	Longmore et al., <i>Can. J. Physiol. Pharmacol.</i> , Vol. 75, pp. 612-621 (1997)						
	C4	Mark S. Kramer et al., <i>Science</i> , Vol. 281, pp. 1640-1645						
	C5	Maggi et al., <i>J. Auton. Pharmacol.</i> , Vol. 13, pp. 23-93 (1993)						
	C6	Navari et al., <i>The New England Journal of Medicine</i> , Vol. 340, No. 3, pp. 190-195 (1999)						
	C7	Maggi et al., <i>Neuropeptides</i> , Vol. 32(1), pp. 1-49 (1998)						
	C8	Doi et al., <i>European Journal of Pharmacology</i> , Vol. 383(3), pp. 297-303 (1999)						
Mnd	C9	Yoshinori Ikeura et al., <i>Chem. Pharm. Bull.</i> , Vol. 45(10), pp. 1642-1652 (1997)						
Examiner Signature	<i>Lorraine V Davis</i>					Date Considered:	3/16/2004	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>4</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

135987